Observes how BCL-2 inhibitor treatments work in routine care for chronic lymphocytic leukemia
Collects real-world records of people with chronic lymphocytic leukemia treated with BCL-2 inhibitor medicines.
Plain-language title generated from the registry record
Registry title: Real-World Study of BCL-2 Inhibitor-Based Regimens in Chronic Lymphocytic Leukemia
Key facts
- Where
- Nanjing, ChinaSee the site
Where in China
- Jiangsu Province HospitalNanjing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The First Affiliated Hospital with Nanjing Medical University
- Trial code
- NCT07874451
- Record updated
- 14 October 2026
- Original description
This non-interventional, real-world cohort study aims to evaluate treatment patterns, clinical outcomes, and safety of BCL-2 inhibitor-based regimens in patients with CLL treated in routine clinical practice. Data collected from participating centers will be used to characterize patient demographics, disease characteristics, treatment exposure, effectiveness outcomes, and adverse events, thereby providing real-world evidence to support clinical decision-making and optimize patient management.Read full original descriptionShow less
A Non-Interventional Real-World Cohort Study Evaluating BCL-2 Inhibitor-Based Treatment Regimens for Patients With Chronic Lymphocytic Leukemia (CLL)
This non-interventional, real-world cohort study aims to evaluate treatment patterns, clinical outcomes, and safety of BCL-2 inhibitor-based regimens in patients with CLL treated in routine clinical practice. Data collected from participating centers will be used to characterize patient demographics, disease characteristics, treatment exposure, effectiveness outcomes, and adverse events, thereby providing real-world evidence to support clinical decision-making and optimize patient management.
Inclusion: Age ≥18 years at the time of enrollment; Confirmed diagnosis of CLL or SLL according to the 2018 iwCLL criteria; Prior or ongoing treatment with a BCL-2 inhibitor-based regimen; Availability of complete key baseline data (e.g., demographic characteristics, disease stage, molecular genetic features, and relevant laboratory parameters) and at least one evaluable post-treatment follow-up record, including effectiveness assessment, safety evaluation, or survival data.
Exclusion: Patients with significant missing key baseline information or treatment exposure data, rendering evaluation of effectiveness or safety outcomes not feasible.